Arvin C. Dar

Memorial Sloan Kettering Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index3.2kcitations112works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(57), PARP inhibition in cancer therapy(26), Lung Cancer Treatments and Mutations(23), Computational Drug Discovery Methods(14), Protein Kinase Regulation and GTPase Signaling(11)

Publications112 total

Advances in BRET probes for intracellular target engagement studies
Nature Chemical Biology·2026
Abstract A064: Chemical and structural mechanisms of RAS induced RAF:KSR dimerization
Molecular Cancer Therapeutics·2025
Abstract A065: Small Molecule Modulation of Inactive-to-Active State Transitions of RAS:RAF-Family Complexes
Molecular Cancer Therapeutics·2025
Mechanisms of resistance to active state selective tri-complex RAS inhibitors
2025· 6 citedOpen Access
Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer
2025Open Access
A stress-responsive p38 signaling axis in choanoflagellates
Figshare·2025Open Access
A stress-responsive p38 signaling axis in choanoflagellates
RSC Chemical Biology·2025· 2 citedOpen Access
Supplementary Table 1 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Methods from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Table 6 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Figures S1-S12 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Table 8 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Table 7 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Methods from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Table 8 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Table 10 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Tables 2-5 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Table 10 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Table 9 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
Supplementary Table 6 from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Frank Sicheri(8), Meagan B. Ryan(7), Bradley Quade(7), Brooke M. Swalm(7), Ayşegül Özen(7), Yongxin Han(7), Klaus P. Hoeflich(7), Margit Hagel(7), Natasha Schenk(6), Zhong Fang(6), Marshall Zingg(6), Steven E. Cohen(6), Chun Li(6), Chaoyang Ye(6), Maria Stella Ritorto(6), Xin Huang(6), Michael Hale(6), Thomas Dever(5), Kevan M. Shokat(5), Z.M. Khan(5)